We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
-2.82%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$3.01B
AUM Growth
-$1.6B
Cap. Flow
-$929M
Cap. Flow %
-30.83%
Top 10 Hldgs %
32.92%
Holding
106
New
21
Increased
16
Reduced
41
Closed
23
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$89.8M
2
BDX icon
Becton Dickinson
BDX
+$70.5M
3
ZTS icon
Zoetis
ZTS
+$66.8M
4
MRK icon
Merck
MRK
+$64.8M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$60.5M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$218M
2
ARGX icon
argenx
ARGX
+$127M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$125M
4
BSX icon
Boston Scientific
BSX
+$113M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$100M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Miscellaneous 0%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARVN icon
1
Arvinas
ARVN
$473M
$117M 3.88%
4,273,900
-676,100
-14% -$21.4M
2020 Q2
11 quarters
SGRY icon
2
Surgery Partners
SGRY
$1.93B
$116M 3.84%
3,355,900
+243,900
+8% +$7.92M
2022 Q3
2 quarters
BIO icon
3
Bio-Rad Laboratories Class A
BIO
$9.61B
$106M 3.52%
221,500
+129,300
+140% +$60.5M
2022 Q3
2 quarters
ARGX icon
4
argenx
ARGX
$51.9B
$105M 3.47%
280,700
-344,300
-55% -$127M
2022 Q1
4 quarters
JAZZ icon
5
Jazz Pharmaceuticals
JAZZ
$13.7B
$99.2M 3.29%
677,900
-49,641
-7% -$7.34M
2022 Q2
3 quarters
REGN icon
6
Regeneron Pharmaceuticals
REGN
$81.9B
$97.9M 3.25%
+119,100
New +$89.8M
2023 Q1
0 quarters
AKRO icon
7
DELISTED
Akero Therapeutics
AKRO
$93.6M 3.11%
2,447,000
-1,378,000
-36% -$61.4M
2022 Q3
2 quarters
THC icon
8
Tenet Healthcare
THC
$22B
$87.5M 2.9%
1,472,000
+754,700
+105% +$41.9M
2022 Q4
1 quarter
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$1.46B
$85.3M 2.83%
2,126,900
-863,100
-29% -$37M
2021 Q3
6 quarters
UHS icon
10
Universal Health Services
UHS
$11.1B
$85.2M 2.83%
670,000
-155,600
-19% -$21.5M
2022 Q4
1 quarter
ACHC icon
11
Acadia Healthcare
ACHC
$2.84B
$84.2M 2.79%
1,165,300
+300
+0% +$23.4K
2022 Q2
3 quarters
NBIX icon
12
Neurocrine Biosciences
NBIX
$14B
$82.6M 2.74%
815,700
-964,300
-54% -$100M
2020 Q4
9 quarters
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$1.2B
$81.6M 2.71%
3,865,300
-1,995,700
-34% -$49.6M
2020 Q2
11 quarters
KRTX icon
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$73.3M 2.43%
403,800
+104,800
+35% +$20M
2022 Q2
3 quarters
BDX icon
15
Becton Dickinson
BDX
$52.7B
$71.3M 2.37%
+288,000
New +$70.5M
2023 Q1
0 quarters
PLRX icon
16
Pliant Therapeutics
PLRX
$59.5M
$70.9M 2.35%
2,665,000
+424,600
+19% +$12.1M
2022 Q3
2 quarters
ZTS icon
17
Zoetis
ZTS
$32.5B
$67.8M 2.25%
+407,500
New +$66.8M
2023 Q1
0 quarters
VTYX icon
18
DELISTED
Ventyx Biosciences
VTYX
$64.2M 2.13%
1,917,800
+632,800
+49% +$24.6M
2022 Q4
1 quarter
MRK icon
19
Merck
MRK
$362B
$63.8M 2.12%
+600,000
New +$64.8M
2023 Q1
0 quarters
SRPT icon
20
Sarepta Therapeutics
SRPT
$1.87B
$57.3M 1.9%
416,000
-639,000
-61% -$82.9M
2022 Q3
2 quarters
LEGN icon
21
Legend Biotech
LEGN
$3.72B
$54M 1.79%
1,120,500
+150,500
+16% +$7.36M
2022 Q4
1 quarter
PRTA icon
22
Prothena Corp
PRTA
$431M
$51.8M 1.72%
1,068,200
-1,884,800
-64% -$99.6M
2022 Q3
2 quarters
IDYA icon
23
IDEAYA Biosciences
IDYA
$3.2B
$50.4M 1.67%
3,673,400
-151,400
-4% -$2.52M
2021 Q1
8 quarters
ZNTL icon
24
Zentalis Pharmaceuticals
ZNTL
$210M
$50.4M 1.67%
2,929,300
-2,220,700
-43% -$45M
2020 Q2
11 quarters
ISEE
25
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$45.5M 1.51%
1,869,200
+1,030,793
+123% +$22.6M
2022 Q4
1 quarter
1
2 3 4 5

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
FGA
Fortis Group Advisors Westwood, New Jersey $626M AUM 33.6% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $626M AUM 199.29% 1-Year Est. Return

Avidity Partners Management's Q1 2023 Portfolio in Review

As of Q1 2023, Avidity Partners Management held 106 positions worth $3.01B, down 35% from $4.62B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Avidity Partners Management withdrew a net $929M in Q1 2023, closing 23 positions and reducing 41 holdings. Its most notable exit was United Therapeutics, an estimated $218M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 92% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Avidity Partners Management opened a new position in Regeneron Pharmaceuticals worth $97.9M.

  • Avidity Partners Management's largest Q1 2023 buy was Regeneron Pharmaceuticals: 119,100 shares worth $97.9M.
  • Avidity Partners Management added most to Bio-Rad Laboratories Class A in Q1 2023, an estimated $60.5M increase.
  • Avidity Partners Management's biggest Q1 2023 reduction was argenx, cutting an estimated $127M.
  • Avidity Partners Management fully exited United Therapeutics in Q1 2023, selling an estimated $218M.
  • Avidity Partners Management's ten largest holdings make up 33% of its $3.01B portfolio in Q1 2023.
  • Avidity Partners Management opened 21 new positions and closed 23 in Q1 2023.
  • Avidity Partners Management's portfolio value fell 35% quarter-over-quarter to $3.01B.

Based on Avidity Partners Management's 13F filing for Q1 2023, filed 15 May 2023.